GlaxoSmithKline (now GSK plc) is a British multinational pharmaceutical and biotechnology company formed through the merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London and operates globally.
Onco-Innovations has begun scaling production of A83B4C63, the API in its lead cancer drug ONC010, to kilogram quantities at Dalton Pharma Services' Toronto facility to support IND-enabling studies. The company's subsidiary Inka Health signed AI research agreements with AstraZeneca and GlaxoSmithKline, and plans a first-in-human study in 2026 pending a pre-IND meeting with the FDA.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
The FDA reversed its refusal to review Moderna's mRNA flu vaccine application after the company amended its submission. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and older, with a decision expected by August 5, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07614360 |
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07609706 |
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment |
NOT_YET_RECRUITING | PHASE1 |
| NCT07607925 |
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07602855 |
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07602777 |
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07600450 |
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive |
NOT_YET_RECRUITING | PHASE1 |
| NCT07596199 |
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women |
NOT_YET_RECRUITING | PHASE3 |
| NCT07596173 |
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years |
NOT_YET_RECRUITING | PHASE3 |
| NCT07591753 |
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study) |
COMPLETED | |
| NCT07585266 |
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) |
NOT_YET_RECRUITING | PHASE3 |
